Leo Seman

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Tim Heise, Elke Seewaldt-Becker, Sreeraj Macha et al. · Diabetes Obesity and Metabolism · 2013 · 271 citations

Medicine, Pharmacokinetics, Pharmacology +15

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska et al. · Diabetes Obesity and Metabolism · 2013 · 210 citations

Medicine, Pharmacology, Pharmacotherapy +17

A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo‐controlled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes

Ele Ferrannini, Leo Seman, Elke Seewaldt-Becker et al. · Diabetes Obesity and Metabolism · 2013 · 181 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects

Ernst J. Schaefer, Judith McNamara, Timothy D. Tayler et al. · The American Journal of Cardiology · 2003 · 159 citations

Medicine, Cardiology, Pharmacotherapy +11

Lipoprotein(a)-Cholesterol and Coronary Heart Disease in the Framingham Heart Study

Leo Seman, C.I. Deluca, J L Jenner et al. · Clinical Chemistry · 1999 · 141 citations · Full text

Medicine, Cardiology, Epidemiologic Methods +14